Literature DB >> 32775350

The Interplay between Alcoholic Liver Disease, Obesity, and the Metabolic Syndrome.

Stephen Malnick1, Yaakov Maor2.   

Abstract

BACKGROUND: Fatty liver may be the result of several factors. The two main contributors are nonalcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD).
SUMMARY: NAFLD is the hepatic manifestation of the metabolic syndrome (MetS) and is the major cause of chronic liver disease worldwide as a result of the obesity epidemic. ALD is also a common cause of chronic liver disease. Obesity is a major contributory factor to MetS and is also common in individuals who consume large amounts of alcohol. There is a similar hepatic pathology and both can result in severe fibrosis, cirrhosis, and its complications including hepatocellular carcinoma. This review discusses the etiology, pathogenesis, and genetics of both NAFLD and ALD and their interaction. It is necessary to understand this better in order to prevent and treat these important causes of liver disease worldwide. KEY MESSAGE: Obesity, MetS, and alcohol consumption are linked to the development and progression of fatty liver disease. The coexistence of these factors in many patients requires a reassessment of many aspects of treatment of fatty liver disease.
Copyright © 2020 by S. Karger AG, Basel.

Entities:  

Keywords:  Alcohol; Fatty liver; Metabolic syndrome

Year:  2020        PMID: 32775350      PMCID: PMC7383260          DOI: 10.1159/000507233

Source DB:  PubMed          Journal:  Visc Med        ISSN: 2297-4725


  73 in total

Review 1.  Alcohol Consumption and the Risk of Type 2 Diabetes: A Systematic Review and Dose-Response Meta-analysis of More Than 1.9 Million Individuals From 38 Observational Studies.

Authors:  Craig Knott; Steven Bell; Annie Britton
Journal:  Diabetes Care       Date:  2015-09       Impact factor: 19.112

2.  Publisher Correction: The gut-liver axis and the intersection with the microbiome.

Authors:  Anupriya Tripathi; Justine Debelius; David A Brenner; Michael Karin; Rohit Loomba; Bernd Schnabl; Rob Knight
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2018-12       Impact factor: 46.802

3.  Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease.

Authors:  Rohit Loomba; Victor Seguritan; Weizhong Li; Tao Long; Niels Klitgord; Archana Bhatt; Parambir Singh Dulai; Cyrielle Caussy; Richele Bettencourt; Sarah K Highlander; Marcus B Jones; Claude B Sirlin; Bernd Schnabl; Lauren Brinkac; Nicholas Schork; Chi-Hua Chen; David A Brenner; William Biggs; Shibu Yooseph; J Craig Venter; Karen E Nelson
Journal:  Cell Metab       Date:  2017-05-02       Impact factor: 27.287

Review 4.  The bidirectional impacts of alcohol consumption and the metabolic syndrome: Cofactors for progressive fatty liver disease.

Authors:  Marie Boyle; Steven Masson; Quentin M Anstee
Journal:  J Hepatol       Date:  2017-11-04       Impact factor: 25.083

5.  Loss of Junctional Adhesion Molecule A Promotes Severe Steatohepatitis in Mice on a Diet High in Saturated Fat, Fructose, and Cholesterol.

Authors:  Khalidur Rahman; Chirayu Desai; Smita S Iyer; Natalie E Thorn; Pradeep Kumar; Yunshan Liu; Tekla Smith; Andrew S Neish; Hongliang Li; Shiyun Tan; Pengbo Wu; Xiaoxiong Liu; Yuanjie Yu; Alton B Farris; Asma Nusrat; Charles A Parkos; Frank A Anania
Journal:  Gastroenterology       Date:  2016-06-21       Impact factor: 22.682

Review 6.  The Prevalence of Metabolic Syndrome in Alcohol Use Disorders: A Systematic Review and Meta-analysis.

Authors:  Davy Vancampfort; Mats Hallgren; James Mugisha; Marc De Hert; Michel Probst; Dirk Monsieur; Brendon Stubbs
Journal:  Alcohol Alcohol       Date:  2016-06-23       Impact factor: 2.826

7.  Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators.

Authors:  Davy Vancampfort; Kristof Vansteelandt; Christoph U Correll; Alex J Mitchell; Amber De Herdt; Pascal Sienaert; Michel Probst; Marc De Hert
Journal:  Am J Psychiatry       Date:  2013-03       Impact factor: 18.112

8.  Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice.

Authors:  Tiphaine Le Roy; Marta Llopis; Patricia Lepage; Aurélia Bruneau; Sylvie Rabot; Claudia Bevilacqua; Patrice Martin; Catherine Philippe; Francine Walker; André Bado; Gabriel Perlemuter; Anne-Marie Cassard-Doulcier; Philippe Gérard
Journal:  Gut       Date:  2012-11-29       Impact factor: 23.059

Review 9.  Pathology of Alcoholic Liver Disease.

Authors:  Romulo Celli; Xuchen Zhang
Journal:  J Clin Transl Hepatol       Date:  2014-06-15

Review 10.  Alcohol consumption and the risk of hypertension in men and women: a systematic review and meta-analysis.

Authors:  Alexandros Briasoulis; Vikram Agarwal; Franz H Messerli
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-09-25       Impact factor: 3.738

View more
  2 in total

Review 1.  Advances in liver organoids: model systems for liver disease.

Authors:  Jaeseo Lee; Seon Ju Mun; Yongbo Shin; Seonbhin Lee; Myung Jin Son
Journal:  Arch Pharm Res       Date:  2022-06-04       Impact factor: 4.946

2.  Synergistic Associations of PNPLA3 I148M Variant, Alcohol Intake, and Obesity With Risk of Cirrhosis, Hepatocellular Carcinoma, and Mortality.

Authors:  Hyun-Seok Kim; Xiangjun Xiao; Jinyoung Byun; Goo Jun; Stacia M DeSantis; Han Chen; Aaron P Thrift; Hashem B El-Serag; Fasiha Kanwal; Christopher I Amos
Journal:  JAMA Netw Open       Date:  2022-10-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.